We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App





Bio-Rad Exhibits Complete Infectious Disease Testing Portfolio at ECCMID 2022

By LabMedica International staff writers
Posted on 26 Apr 2022
Print article
Image: ADAGIO system and antibiotic susceptibility discs (Photo courtesy of Bio-Rad)
Image: ADAGIO system and antibiotic susceptibility discs (Photo courtesy of Bio-Rad)

Bio-Rad Laboratories (Hercules, CA, USA) exhibited its complete range of infectious disease testing systems, reagents and quality controls for optimizing testing workflows and providing quality results at ECCMID 2022.

Increasing antibiotic resistance among microbial populations is one of the major public health concerns. To fight antibiotic resistance spread, AST Systems must allow biologists to accurately diagnose specific resistance phenotypes, according to official CLSI & EUCAST guidelines. At this year’s ECCMID, Bio-Rad exhibited its complete and up-to-date range of antimicrobial susceptibility testing products, from AST reagents to the ADAGIO system, dispenser, and susceptibility media. The ADAGIO Antimicrobial Susceptibility Testing System is an automated imaging device that reads and interprets antibiotic disks and MIC strips. The Bio-Rad automatic disk recognition feature improves the reading process for reliability and confidence in your result interpretation. The ADAGIO system is designed to fit into the microbiology laboratory organization and to provide high-quality AST results. Patient data results are securely stored in the ADAGIO software allowing accurate epidemiology studies to be built based on customized statistical analysis. Bio-Rad also demonstrated its comprehensive line of antimicrobial susceptibility disks for semi-quantitative in vitro susceptibility testing of previously isolated pure cultures of microorganisms.

Additionally, Bio-Rad highlighted its full range of serological immunoassay reagents, testing systems, and expertise for meeting mycology testing challenges. Among its mycology testing solutions, Bio-Rad demonstrated its serological assays for detecting antigens of Candida, Aspergillus, and Cryptococcus neoformans as well as antibodies using standardized antigens of Candida and Aspergillus. The company also demonstrated how its EIA microplate-based assays for mycology testing can be performed using manual, semi-automated, or fully-automated instrument systems including its EVOLIS Systems. The EVOLIS and the EVOLIS Twin Plus systems assure the highest level of laboratory safety with positive identification of samples and reagents and a unique triple pipetting verification technology (capacitive, barometric & colorimetric detection).

Bio-Rad also presented its Geenius Confirmatory Solution to help labs confirm and differentiate individual antibodies to HIV-1 and HIV-2 and to confirm the presence of anti-HCV antibodies. The company also demonstrated its high-performance screening assays for the detection of HIV, HCV, HBV, and syphilis along with comprehensive systems that ensure reliable and safe results for blood donor screening.

Related Links:
Bio-Rad Laboratories 

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
PSA Test
Humasis PSA Card

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.